Interstitial lung disease with ANCA-associated vasculitis

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Volumn 9, Issue , 2015, Pages 51-56

  Katsumata, Yasuhiro ^a   Kawaguchi, Yasushi ^a   Yamanaka, Hisashi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis; Interstitial lung disease; Microscopic polyangiitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYPOCHLOROUS ACID; MIZORIBINE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CELL ACTIVATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG INDICATION; ENZYME ACTIVATION; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LUNG HEMORRHAGE; MICROSCOPIC POLYANGIITIS; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; PHENOTYPE; PREVALENCE; PROGNOSIS; RADIODIAGNOSIS; SMOKING; TRANSBRONCHIAL BIOPSY; VIDEO ASSISTED THORACOSCOPIC SURGERY;

EID: 84942807748     PISSN: 11795484     EISSN: 11795484     Source Type: Journal    
DOI: 10.4137/CCRPM.S23314     Document Type: Article

References (22)

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11.
2. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222–227.
3. Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc. 1990;65:847–56.
4. Arimura Y, Minoshima S, Tanaka U, et al. [Pulmonary involvement in patients with myeloperoxidase specific-antineutrophil cytoplasmic antibody]. Ryumachi. 1995;35:46–55. [in Japanese]
5. Hirayama K, Kobayashi M, Usui J, et al. Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol Dial Transplant. 2015;30 Suppl 1:183–193.
6. Sada KE, Yamamura M, Harigai M, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16:R101.
7. Ando M, Miyazaki E, Ishii T, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107:608–15.
8. Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2:e000058.
9. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004;9:190–196.
10. Arulkumaran N, Periselneris N, Gaskin G, et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford). 2011;50:2035–2043.
11. Tzelepis GE, Kokosi M, Tzioufas A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J. 2010;36:116–121.
12. Fernandez Casares M, Gonzalez A, Fielli M, Caputo F, Bottinelli Y, Zamboni M. Microscopic polyangiitis associated with pulmonary fibrosis. Clin Rheumatol. 2015;34:1273–1277.
13. Hervier B, Pagnoux C, Agard C, et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009;68:404–7.
14. Foulon G, Delaval P, Valeyre D, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med. 2008;102:1392–1398.
15. Comarmond C, Crestani B, Tazi A, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore). 2014;93:340–349
16. Katsuyama T, Sada KE, Makino H. Current concept and epidemiology of systemic vasculitides. Allergol Int. 2014;63:505–513.
17. Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford). 2011;50:1916–1920.
18. Homma S, Suzuki A, Sato K. Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist. Clin Exp Nephrol. 2013;17:667–671.
19. Schnabel A, Reuter M, Csernok E, Richter C, Gross WL. Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. Eur Respir J. 1999;14:118–124.
20. Guilpain P, Chereau C, Goulvestre C, et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J. 2011;37:1503–13.
21. Foucher P, Heeringa P, Petersen AH, et al. Antimyeloperoxidase-associated lung disease. An experimental model. Am J Respir Crit Care Med. 1999;160:987–994.
22. Churg A, Zay K, Shay S, et al. Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am J Respir Cell Mol Biol. 2002;27:368–374.